Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Targeted Anticancer Therapies – TAT 2013

TAT 2013 banner
Start date
04 Mar 2013
End date
06 Mar 2013
Paris, France

TAT 2013 was attended by over 500 participants from 46 countries, surpassing the number of delegates attending the previous two meetings in Paris and Amsterdam. The 12 plenary sessions comprised 61 lectures presented by leading experts in clinical cancer research and oncology drug development. 

TAT 2013 was held in Paris under the presidency of Professor Jean-Charles Soria, Institut Gustave Roussy, Villejuif, France. In his welcome address, the congress president emphasised the pivotal role of the TAT congress series in identifying the most promising new cancer drugs and guiding them through the critical early phases of clinical development.  The focus of TAT congresses is at early-phase clinical studies of innovative cancer therapeutics and translational research.

Access the meeting resources on OncologyPRO OncologyPRO Logo

New drugs and targets discussed this year:

  • New immune checkpoints (PD-1, PD-L1): four major drug development programmes were reviewed
  • Metabolic drug targets: three major drug development programmes were reviewed
  • Drug targeting the RAS-RAF-MEK pathway: drugs for BRAF-, KRAS-mutant tumours, drug combinations involving MEK inhibition
  • Immunoconjugates and TLR ligand-long peptide conjugates
  • Several drugs in phase 1 studies:  e.g., a new androgen-targeting agent, a p43-targeting compound, an Akt inhibitor, a liposomal siRNA targeting protein kinase N3, a second-generation hypomethylating agent, everolimus in combination with radiotherapy, a histone deacetylase inhibitor
  • Many drugs and targets in various phases of (pre)clinical development, overall dozens of agents and targets

Oncology Biotech Event

In addition to discussing new drugs and targets, the TAT 2013 programme addressed methodological issues in cancer drug development, such as the use of whole-genome sequencing in patient selection for targeted therapies and the value and limitations of preclinical models in drug discovery and development.

This year the congress featured for the first time the “Oncology Biotech Event”, providing biotech companies in oncology opportunities for networking and partnering with the world's academic leaders in early-phase clinical and translational cancer research.

TAT 2013 was offered by NDDO Education Foundation, in a partnership with the European Society for Medical Oncology (ESMO) and co-sponsored by the U.S. National Cancer Institute (NCI)/Center for Cancer Research (CCR).

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.